Patients Related Topics 
Fierce Pharma
MAY 28, 2024
A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen drugmakers potentially affected. | The potentially compromised data included patient information such as names and addresses, Cencora disclosed in letters to patients who may have been affected.
Fierce Pharma
JUNE 18, 2024
Authors: Arlene Pineda, Senior Director, Patient Support Services, IQVIA Kristina Jones, Principal, Patient Services Technology & Analytics, IQVIA | In a curious twist, patient support programs — often designed to alleviate the burden on patients — sometimes create unintended challenges.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 6, 2023
IBM disclosed "unauthorized access" to J&J’s Janssen CarePath patient assistance program, which helped over 1 million U.S. patients last year.
Fierce Pharma
JULY 15, 2024
million gene therapy Casgevy for sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), patients must first undergo chemotherapy | Vertex has filed a lawsuit in federal court in Washington, D.C. To receive Vertex and CRISPR Therapeutics’ $2.2 against the U.S.
Advertisement
Deviations from the intended supply chain can delay timelines and affect these high value products, which can be detrimental to budgets, but more importantly can have dire effects on the patients whose lives depend on receiving these critical doses safely and on time.
Fierce Pharma
MARCH 7, 2024
As one of Boehringer Ingelheim's asthma competitors catches scrutiny over pricing and access concerns, the company itself is taking steps to cut patient costs in the U.S. Starting on June 1, patients will only have to shell out a maximum of $35 per month for Boehringer Ingelheim inhalers in the U.S.
Fierce Pharma
MAY 9, 2024
While Vertex leads in patient starts, bluebird has activated more treatment centers. It’s not an easy question to answer.
Advertisement
The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. There’s been a rapid shift towards decentralization in clinical trials & it’s clear why.
Advertisement
An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays.
Advertisement
Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. Clinical trial data management is increasingly challenging as studies grow in complexity. In this paper, we explore real-time data access and analysis for proactive study management.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
Learning Objectives: Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development? Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.
Expert insights. Personalized for you.
320 
Let's personalize your content